• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

    10/11/24 10:50:00 AM ET
    $ACXP
    $BURU
    $ZAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ACXP alert in real time by email

    Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week

    NEW YORK, NY / ACCESSWIRE / October 11, 2024 / New to The Street, the leading platform for showcasing innovative companies, is proud to announce its upcoming sponsored programming on Bloomberg TV airing Saturday, October 11, at 6:30 PM EST. The lineup includes ZAPP, NUBURU, and ACURX Pharmaceuticals, each bringing cutting-edge advancements in electric vehicles, blue laser technology, and antibiotic innovation to the forefront.

    Reuters NTTS
    Reuters NTTS

    In addition to these groundbreaking features, The Sustainable Green Team will highlight their eco-friendly solutions aimed at promoting environmental sustainability, while SEKUR will return with its fan-favorite segment, "Hack of the Week," delivering crucial insights into the latest cybersecurity threats and privacy protection.

    About Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ($ZAPP)

    Zapp EV (NASDAQ:ZAPP) ($ZAPP) and its operating subsidiaries are run by a team of experts from the mobility industry on a mission to redefine the electric two-wheeler segment. Zapp's debut product, the i300, is an urban electric high-performance two-wheeler capable of traditional motorcycle performance levels in a step-through format, combining ease of use with exhilaration and fun. For more information, visit www.zappev.com.

    About NUBURU (NYSE AM: BURU)

    Founded in 2015, NUBURU, Inc. (NYSE AM: BURU) is a developer and manufacturer of industrial blue lasers that leverage fundamental physics and their high-brightness, high-power design to produce faster, higher-quality welds and parts in laser welding and additive manufacturing of copper, gold, aluminum, and other industrially important metals. For more information, visit www.nuburu.net.

    About Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ($ACXP)

    Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ($ACXP) is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The Company's pipeline includes product candidates targeting Gram-positive bacteria, such as Clostridioides difficile and MRSA. For more information, visit www.acurxpharma.com.

    About The Sustainable Green Team (SGTM)

    The Sustainable Green Team provides eco-friendly waste management and sustainability solutions to help businesses and municipalities manage waste and promote recycling. Their efforts contribute to reducing landfill usage and advancing the circular economy across industries.

    About SEKUR

    SEKUR is a leading provider of cybersecurity and privacy solutions with encrypted email and messaging platforms that safeguard both individuals and businesses from cyber threats. Their "Hack of the Week" segment shares insights into the latest trends in data security.

    About New to The Street

    New to The Street is a premier television program that has been profiling public and private companies since 2009, airing as sponsored programming on major networks like Fox Business and Bloomberg. In addition to its nationwide broadcasts, New to The Street showcases its interviews on one of the most powerful YouTube channels, with over 1.6 million subscribers, and features the strongest social media platforms for interviews in the business. The program reaches millions of households in the U.S. and internationally.

    For media inquiries, contact:
    Monica Brennan
    New to The Street
    [email protected]

    Contact Information:

    Monica Brennan
    Head of Operations
    [email protected]

    SOURCE: New to The Street



    View the original press release on accesswire.com

    Get the next $ACXP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $BURU
    $ZAPP

    CompanyDatePrice TargetRatingAnalyst
    Acurx Pharmaceuticals Inc.
    $ACXP
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    $BURU
    $ZAPP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NUBURU Strengthens Balance Sheet, Advances Defense-Tech Acquisition Program and Revamps Blue-Laser Business

    Executing Transformation Plan spanning Maddox Defense drones, Tekne special-mission vehicles, and Orbit critical-infrastructure software to build a unified defense-tech platform with expanding NATO traction. Blue-laser technology' business acquisition on track. NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company") continued strengthening its balance sheet during the quarter through disciplined capital deployment, selective drawdowns under its Standby Equity Purchase Agreement when beneficial, and further reduction of legacy payables. Cash on hand remains robust as NUBURU strategically allocates capital to high-value defense and security growth initiatives under its Transformation Plan. "We

    11/6/25 7:30:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    NUBURU Completes First Phase of Orbit Acquisition, Advancing Software-Driven Defense & Security Platform Into Multi-Billion-Dollar Market

    Initial funding boost secures strategic foothold in high-growth operational-resilience technologies and accelerates path toward controlling stake NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company"), a global pioneer in blue-laser innovation advancing defense and security transformation, today announced the completion of the first phase of its planned acquisition of Orbit S.r.l. ("Orbit"). Nuburu Defense LLC ("Nuburu Defense") has made an initial capital infusion of $1.5 million into Orbit through a subscribed capital increase, securing a 10.7% equity position. Orbit is a defense-grade SaaS company specializing in operational resilience, business continuity, and crisis-management digita

    10/31/25 7:00:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

    Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC inhibitor, ibezapolstat (IBZ), has unique selective antibacterial activity in the gut which spares beneficial bile acid-metabolizing bacteriaThe favorable gut bile acid profile contributes to ibezapolstat's anti-recurrence effect in patients with C. difficile Infection (CDI)New data presented on representative novel compounds from Acurx's DNA pol IIIC inhibitor preclinical pipeline provide initial evidence that microbiome selectivity, when compared to the comparator antibiotic, linezolid, may be a class effectIbezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA; Acurx's preclinical an

    10/28/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $BURU
    $ZAPP
    SEC Filings

    View All

    Nuburu Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Nuburu, Inc. (0001814215) (Filer)

    11/6/25 5:10:27 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

    S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    10/20/25 4:01:52 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuburu Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Nuburu, Inc. (0001814215) (Filer)

    10/7/25 5:10:26 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $ACXP
    $BURU
    $ZAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    11/29/21 8:33:36 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $BURU
    $ZAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:47:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Luci David P

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:46:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Deluccia Robert J

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:45:47 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $BURU
    $ZAPP
    Leadership Updates

    Live Leadership Updates

    View All

    NUBURU Strengthens Balance Sheet, Advances Defense-Tech Acquisition Program and Revamps Blue-Laser Business

    Executing Transformation Plan spanning Maddox Defense drones, Tekne special-mission vehicles, and Orbit critical-infrastructure software to build a unified defense-tech platform with expanding NATO traction. Blue-laser technology' business acquisition on track. NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company") continued strengthening its balance sheet during the quarter through disciplined capital deployment, selective drawdowns under its Standby Equity Purchase Agreement when beneficial, and further reduction of legacy payables. Cash on hand remains robust as NUBURU strategically allocates capital to high-value defense and security growth initiatives under its Transformation Plan. "We

    11/6/25 7:30:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Zapp EV Appoints Authorised Reseller in Ireland

    LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced it has appointed Michael Grant Zapp Limited as its first authorised reseller in Ireland, based in Dublin. Mr. Michael Grant brings more than 40 years of experience in automotive retail businesses to this newly-formed venture dedicated to the sale and support of electric vehicles. David McIntyre, Chief Operating Officer of Zapp EV, said: "We are excited to start working with our first Irish authorised reseller following recent European homologatio

    4/29/25 7:05:00 AM ET
    $ZAPP
    Motor Vehicles
    Consumer Discretionary

    Zapp EV Appoints Its First Authorised Reseller in Europe

    LONDON, March 31, 2025 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced it has appointed Green Mopeds Ltd. ("Green Mopeds") as its first authorised reseller of Zapp's urban electric motorcycle, i300, throughout Great Britain. Customers will be able to see i300 on display and arrange for test-rides from the Green Mopeds location in West London. In addition, Green Mopeds will provide delivery and after-sales support utilising Zapp's proprietary drop-ship-direct-to-customer premium service model.  Zapp anticipa

    3/31/25 6:05:00 AM ET
    $ZAPP
    Motor Vehicles
    Consumer Discretionary

    $ACXP
    $BURU
    $ZAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $BURU
    $ZAPP
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date:                           Wednesday, November 12, 2025 Time:                       

    10/27/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUBURU Restores NYSE Compliance and Strengthens Defense Transformation With Its Acquisition Plan Underway

    Technical communication issue resolved earlier this week; dual-CEO team driving rapid expansion, regulatory excellence, and new stages of growth across defense and industrial innovation sectors NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company"), a pioneer in next-generation blue-laser defense and advanced manufacturing technologies, today reaffirmed that it remains in full compliance with NYSE American regulatory disclosure requirements. This statement follows the resolution of a technical communication timing issue earlier this week, which was related to the coordination of press release dissemination with the Exchange. The Company received a non-compliance warning earlier this week

    10/16/25 7:00:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2025.   Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, we announced that the Indian Patent Office granted a new patent for our DNA polymerase IIIC inhibitors which expires in December 2039, subject to extension. This constitutes another significant building block for our ongoing preclinical antib

    8/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $BURU
    $ZAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nuburu Inc.

    SC 13D/A - Nuburu, Inc. (0001814215) (Subject)

    11/25/24 8:59:19 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Nuburu Inc.

    SC 13G - Nuburu, Inc. (0001814215) (Subject)

    8/12/24 8:59:36 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/24 2:39:21 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care